secwatch.observer — SEC 8-K summary
======================================

Issuer:     IDEXX LABORATORIES INC /DE (IDXX)
CIK:        0000874716
Form:       8-K
Filed at:   2024-10-31T23:59:59+00:00
Accession:  0001104659-24-112826
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IDEXX Q3 EPS $2.80, revenue $976M; cuts FY24 revenue guidance citing macro headwinds
--------------------------------------------------------------------------------

- Q3 revenue $976M (+7% reported, +6% organic); EPS $2.80 (+11% reported, +12% comparable).
- CAG Diagnostics recurring revenue +7% reported and organic; global premium instrument installed base +10% YoY.
- FY24 revenue guidance cut $38M at midpoint to $3,865M-$3,890M; organic growth now 5.3%-6.0% (prior 6.2%-7.8%).
- EPS guidance narrowed to $10.37-$10.53, midpoint unchanged; $0.56 negative impact from litigation accrual.
- Water revenue +13%; LPD -3%. Gross margin 61.1% (+120 bps). Operating margin 31.2% (+110 bps).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874716/000110465924112826/0001104659-24-112826-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874716/000110465924112826/tm2427157d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-112826

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer